180 related articles for article (PubMed ID: 10597772)
21. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
23. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
[TBL] [Abstract][Full Text] [Related]
24. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
25. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
26. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
27. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
28. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.
Duran S; Spire B; Raffi F; Walter V; Bouhour D; Journot V; Cailleton V; Leport C; Moatti JP;
HIV Clin Trials; 2001; 2(1):38-45. PubMed ID: 11590513
[TBL] [Abstract][Full Text] [Related]
29. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
30. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
[TBL] [Abstract][Full Text] [Related]
31. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
Ena J; Amador C; Benito C; Fenoll V; Pasquau F
Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
[TBL] [Abstract][Full Text] [Related]
32. Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study.
Mussi-Pinhata MM; Rego MA; Freimanis L; Kakehasi FM; Machado DM; Cardoso EM; Read JS;
Pediatr Infect Dis J; 2007 Nov; 26(11):1032-7. PubMed ID: 17984811
[TBL] [Abstract][Full Text] [Related]
33. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA
AIDS; 2003 Oct; 17(15):2191-9. PubMed ID: 14523276
[TBL] [Abstract][Full Text] [Related]
34. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
[TBL] [Abstract][Full Text] [Related]
35. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.
Brown TT; Li X; Cole SR; Kingsley LA; Palella FJ; Riddler SA; Chmiel JS; Visscher BR; Margolick JB; Dobs AS
AIDS; 2005 Sep; 19(13):1375-83. PubMed ID: 16103768
[TBL] [Abstract][Full Text] [Related]
36. Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy.
Otegbayo JA; Kuti MA; Ogunbode O; Irabor AE; Adewoles IF
Afr J Med Med Sci; 2012 Dec; 41(4):417-22. PubMed ID: 23672107
[TBL] [Abstract][Full Text] [Related]
37. Vitamin E concentrations in adults with HIV/AIDS on highly active antiretroviral therapy.
Itinoseki Kaio DJ; Rondó PH; Luzia LA; Souza JM; Firmino AV; Santos SS
Nutrients; 2014 Sep; 6(9):3641-52. PubMed ID: 25225815
[TBL] [Abstract][Full Text] [Related]
38. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
39. Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Yamamoto Y; Yasuoka A; Tachikawa N; Teruya K; Genka I; Yamaguchi M; Yasuoka C; Kikuchi Y; Aoki M; Oka S
Jpn J Infect Dis; 1999 Dec; 52(6):248-9. PubMed ID: 10738365
[No Abstract] [Full Text] [Related]
40. [First antiretroviral therapy regimen in HIV-infected patients. Durability and factors associated with therapy changes].
de la Torre J; Santos J; Perea-Milla E; Pérez I; Moreno F; Palacios R; Santamaría S; Del Arco A; Nuño E; Godoy M; Prada JL; Olalla J; Aguilar J; Martos F;
Enferm Infecc Microbiol Clin; 2008; 26(7):416-22. PubMed ID: 18842236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
